Canagliflozin tablets

Form: Tablets

Strength: 100 mg and 300 mg

Reference Brands: Invokana(US & EU)

Category: Diabetes

Canagliflozin is an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor used for managing type 2 diabetes and reducing cardiovascular and renal risks. Approved by the FDA in 2013 under the brand Invokana (100 mg, 300 mg), it received EU approval via centralized procedure the same year. It may be used as monotherapy or in combination with other antidiabetic agents. Canagliflozin lowers blood glucose by promoting urinary glucose excretion. Periodic renal assessment is recommended. Through Pharmatradz.com, B2B pharmaceutical buyers can source Canagliflozin from globally audited manufacturers and exporters, ensuring compliance with USA FDA and EU EMA regulatory standards.